Alembic Pharmaceuticals Limited — PPTs, 15-05-2026: Investor Presentation

Alembic Pharmaceuticals reported a robust Q4 FY26 with revenue at 1848 Cr (+4% YoY) and full-year revenue of 7345 Cr (+10% YoY). Profit After Tax (PAT) for Q4 jumped 29% YoY to 203 Cr, while full-year PAT grew 16% to 675 Cr. Pre R&D EBITDA stood at 455 Cr (+29% YoY) with a healthy 25% margin.

India Branded business grew 4% in Q4, with Animal Health soaring 27%. US Formulation delivered an impressive 11% growth, boosted by new product launches and market share gains. The company successfully launched its first US branded product, 'Pivya', in Q4 and added 15 new products in the US for FY26. R&D spend increased, supporting higher filings and peptide development, signaling a strong pipeline focus.

Strategic initiatives include expanding its US branded footprint, geographical diversification for ex-US markets like Thailand and Germany, and exploring injectables. The company also highlighted its commitment to sustainability with a Net Zero target by 2050 and water neutrality by 2027.